Veracyte Secures Medicare Reimbursement for Prosigna Breast Cancer Test
Veracyte said Medicare reimbursement has been secured for its Prosigna test, which assesses breast cancer recurrence risk.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Veracyte secures Medicare reimbursement for Prosigna test
Veracyte secured Medicare reimbursement for its Prosigna breast risk-of-recurrence test.